Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB)

Raymond James Financial Inc. purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 475,551 shares of the company’s stock, valued at approximately $2,221,000. Raymond James Financial Inc. owned 2.15% of INmune Bio as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Financial Advocates Investment Management increased its stake in shares of INmune Bio by 14.8% in the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers boosted its holdings in INmune Bio by 16.9% in the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after buying an additional 2,424 shares during the period. Fermata Advisors LLC boosted its holdings in INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after buying an additional 4,267 shares during the period. Jane Street Group LLC purchased a new position in INmune Bio in the 3rd quarter valued at approximately $79,000. Finally, Westside Investment Management Inc. raised its holdings in INmune Bio by 26.2% during the 4th quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock valued at $420,000 after acquiring an additional 18,660 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on INMB. Scotiabank raised their price target on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw started coverage on INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target on the stock. Finally, Maxim Group raised their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, INmune Bio has an average rating of “Buy” and a consensus target price of $22.80.

INmune Bio Stock Up 1.5 %

Shares of NASDAQ INMB opened at $7.52 on Monday. The stock’s 50-day simple moving average is $8.41 and its two-hundred day simple moving average is $6.38. INmune Bio, Inc. has a twelve month low of $4.32 and a twelve month high of $12.72. The firm has a market capitalization of $199.96 million, a P/E ratio of -3.45 and a beta of 1.93.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.14. As a group, research analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.